Secondary acute myelogenous leukemia following safe exposure to etoposide
| Autor: | Kimo C. Stine, David L. Becton, R L Saylors, J R Sawyer |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Cancer Research
Chemotherapy medicine.medical_specialty Vincristine business.industry medicine.medical_treatment Bleomycin medicine.disease Gastroenterology Surgery Lymphoma Radiation therapy chemistry.chemical_compound Histiocytosis Oncology chemistry Internal medicine Medicine business Complication Etoposide medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 15:1583-1586 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1997.15.4.1583 |
| Popis: | PURPOSE To present two patients as illustrations of the risk of developing secondary acute myelogenous leukemia (sAML) when theoretically safe doses of etoposide (VP-16) are used. PATIENTS AND METHODS Patient no. 1 was a 15-year-old white girl diagnosed with stage IIa Hodgkin's disease. She was treated with a combination of vincristine, doxorubicin, bleomycin, and VP-16 (2 g/m2 total) over 4 months, followed by 25.5 Gy of involved-field radiotherapy. Patient no. 2 was an 11-year-old white boy diagnosed with virus-associated hemophagocytic syndrome (VAHS). He was treated with VP-16 intravenously (IV) and orally (0.3 g and 2.8 g/m2, respectively). RESULTS Patient no. 1 developed AML 16 months from the diagnosis of Hodgkin's disease. Patient no. 2 developed AML 26 months from diagnosis. Both bone marrows were consistent with French-American-British (FAB) M4 disease. Both patients had abnormalities of the long arm of chromosome 11. CONCLUSION The use of low-dose or oral VP-16 can be associated with the development of sAML. Clinicians should be cautious in the use of VP-16 in low-risk diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|